share_log

BriaCell Therapeutics Reports Preliminary Survival And Clinical Benefit Data In A New Subset Of Advanced Breast Cancer Patients Treated With BriaCell's Bria-IMT Regimen: Patients That Have Developed Resistance To Antibody-Drug Conjugates

Moomoo 24/7 ·  Dec 20, 2023 08:42
  • In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell's combination regimen exceeded that of similar studies*
  • Progression Free Survival (PFS) was similar or better than last regimen in 40% of the patients highlighting clinical efficacy
    • Disease control rate of 40% was observed in evaluable patients further indicating clinical benefit
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment